Loading...
This is another report from the discontinued, estrogen-only arm of the WHI’s hormone therapy trial (Journal Watch Women’s Health Jun 9 2004). In this arm of the trial, 10,739 postmenopausal women (age range, 50–79) who previously had undergone hysterectomy were randomized to receive conjugated estrogen (0.625 mg/day) or placebo.
When this arm was terminated after a mean 6.8 years of follow-up, the data showed no association between estrogen use and the primary outcome: coronary heart disease (CHD), defined as nonfatal myocardial infarction or coronary death. Now, researchers have reported final data on coronary events through a mean 7.1 years of follow-up.
The incidence of CHD did not differ significantly between the estrogen and placebo grou…